@article{oai:nagasaki-u.repo.nii.ac.jp:00008533,
 author = {Shibata, Itsuko and Cho, Sungsam and Yoshitomi, Osamu and Ureshino, Hiroyuki and Maekawa, Takuji and Hara, Tetsuya and Sumikawa, Koji},
 issue = {1},
 journal = {Scandinavian Cardiovascular Journal},
 month = {Feb},
 note = {Objectives. We assessed the effect of milrinone application timing after reperfusion against myocardial stunning as compared with levosimendan in swine. Furthermore, we examined the role of p38 mitogen-activated protein kinase (p38 MAPK) in the milrinone-induced cardioprotection. Design. All swine were subjected to 12-minutes ischemia followed by 90-minutes reperfusion to generate stunned myocardium. Milrinone or levosimendan was administered intravenously either for 20 minutes starting just after reperfusion or for 70 minutes starting 20 minutes after reperfusion. In another group, SB203580, a selective p38 MAPK inhibitor, was administered with and without milrinone. Regional myocardial contractility was assessed by percent segment shortening (%SS). Results. Milrinone starting just after reperfusion, but not starting 20 minutes after reperfusion, improved %SS at 30, 60, and 90 minutes after reperfusion compared with that in the control group. SB203580 abolished the beneficial effect of milrinone. On the other hand, levosimendan starting 20 minutes after reperfusion, but not for 20 minutes starting just after reperfusion, improved %SS at 60 and 90 minutes after reperfusion. Conclusions. Milrinone should be administered just after reperfusion to protect myocardial stunning through p38 MAPK, whereas levosimendan improvement of contractile function could be mainly dependent on its positive inotropic effect., Scandinavian Cardiovascular Journal, 47(1), pp.50-57; 2013},
 pages = {50--57},
 title = {Milrinone and levosimendan administered after reperfusion improve myocardial stunning in swine},
 volume = {47},
 year = {2013}
}